Facial Dermatitis
Conditions
Interventions
test:La Roche-Posay new B5 Multi-Repair Cream, 50g/tube, for external use in an appropriate amount, manufactured by L'Oréal (China) Co., Ltd.
control:Single Cream, 20g/tube, for external use in an appropriate amount, manufactured by Shanghai Dermatology Hospital.
Sponsors
Shanghai Skin Disease Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Age range: 18-70 years, both genders are eligible. 2.Individuals with clinically recurrent facial dermatitis that has undergone treatment and whose skin lesions have improved, currently in the subclinical repair phase. 3.Exhibiting manifestations of sensitive skin conditions, and in accordance with Baumann's criteria, classified as having sensitive skin. 4.Willing to accept and strictly adhere to the treatment protocol stipulated by the study. 5.Understanding and voluntarily signing the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Individuals who are in the process of preparing for pregnancy, pregnant, or lactating. 2.Those with severe organ dysfunction or mental disorders. 3.Patients with uncontrolled chronic conditions such as diabetes or hypertension. 4.Patients with rosacea, atopic dermatitis, corticosteroid-dependent dermatitis, or those with dermatitis and eczema in the active stage. 5.Individuals who have undergone photodynamic therapy, drug injection, laser treatment, or other photoelectric treatments on the face within the past month. 6.Those who have systemically used antibiotics, doxycycline, or other anti-sensitivity medications within the past month. 7.Patients who have applied topical antibiotics, tacrolimus, pimecrolimus, or other anti-sensitivity medications on the face within the past two weeks. 8.Individuals who are concurrently using other cosmetics with anti-sensitivity or repair properties on the face during the trial. 9.Known allergy to test instrument contact materials (such as gel, patches). 10.Participants who have been involved in or are currently participating in other clinical trials within the past two months prior to the start of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Transepidermal water loss rate(TEWL);Water content of the stratum corneum(WCSC);Dermal - epidermal density of the skin;Skin Thickness Measurement; | — |
Secondary
| Measure | Time frame |
|---|---|
| alpha diversity;beta - diversity; | — |
Countries
China
Contacts
Public ContactYing Zou
Shanghai Skin Disease Hospital
Outcome results
None listed